封面
市场调查报告书
商品编码
1691774

基于组学的临床试验市场 - 全球产业规模、份额、趋势、机会和预测,按阶段、按研究设计、按适应症、按地区和竞争进行细分,2020-2030 年预测

Omics-Based Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Phase, By Study Design, By Indication, By Region & Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球基于组学的临床试验市场价值为 266.7 亿美元,预计在预测期内将经历大幅增长,到 2030 年的年复合成长率(CAGR) 为 7.25%。基于组学的临床试验整合了先进的组学技术,以收集参与临床研究的患者的详细分子资料。组学涵盖了生物学和医学中用于在分子水平上分析生物分子的一系列高通量技术。这些技术包括基因组学(研究基因和 DNA)、蛋白质组学(研究蛋白质)、代谢组学(研究小分子和代谢物)、转录组学(研究 RNA 和基因表现)等。基于组学的临床试验的一个主要目标是根据患者的分子特征将其分成亚组,从而实现更有针对性和个性化的医疗干预。

市场概况
预测期 2026-2030
2024 年市场规模 266.7 亿美元
2030 年市场规模 402.6 亿美元
2025-2030 年复合年增长率 7.25%
成长最快的领域 干预性研究
最大的市场 北美洲

然而,基于组学的临床试验面临资料标准化、可重复性问题以及对先进生物资讯能力的需求等挑战。组学资料的准确性和可靠性对于试验的成功至关重要。例如,2024 年 4 月发表的一篇文章强调了基于组学的生物标记在管理代谢功能障碍相关脂肪变性肝病 (MASLD) 方面日益增长的重要性,这些生物标记有助于风险分层和识别不良后果风险较高的晚期纤维化患者。基于组学的临床试验的日益普及预计将进一步推动市场成长。

主要市场驱动因素:

组学技术的进步

主要市场挑战:

样本大小和多样性

主要市场趋势:

多组学资料整合

目录

第 1 章:产品概述

第 2 章:研究方法

第 3 章:执行摘要

第 4 章:顾客之声

第 5 章:全球基于组学的临床试验市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 按阶段(第一阶段、第二阶段、第三阶段和第四阶段)
    • 依研究设计(扩大准入研究、介入性研究和观察性研究)
    • 按适应症(心臟病学、中枢神经系统疾病、遗传疾病、免疫学、肿瘤学、呼吸系统疾病和皮肤病)
    • 按地区
    • 按公司分类(2024)
  • 市场地图

第 6 章:亚太地区基于组学的临床试验市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区:国家分析
    • 印度
    • 澳洲
    • 日本
    • 韩国

第 7 章:欧洲基于组学的临床试验市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲:国家分析
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 8 章:北美基于组学的临床试验市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美:国家分析
    • 墨西哥
    • 加拿大

第 9 章:南美洲基于组学的临床试验市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲:国家分析
    • 阿根廷
    • 哥伦比亚

第 10 章:中东和非洲基于组学的临床试验市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA:国家分析
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章:市场动态

  • 驱动程式
  • 挑战

第 12 章:市场趋势与发展

  • 最新动态
  • 产品发布
  • 合併与收购

第 13 章:全球基于组学的临床试验市场:SWOT 分析

第 14 章:波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章: 大环境分析

第 16 章:竞争格局

  • Parexel International Corporation
  • Pharmaceutical Product Development (PPD)
  • Charles River Laboratory
  • ICON plc
  • SGS SA
  • Eli Lilly and Company
  • Pfizer Inc.
  • Covance Inc.
  • Novo Nordisk
  • Rebus Bio

第 17 章:策略建议

第18章调查会社について・免责事项

简介目录
Product Code: 18961

The global Omics-Based Clinical Trials Market was valued at USD 26.67 billion in 2024 and is projected to experience substantial growth during the forecast period, with a compound annual growth rate (CAGR) of 7.25% through 2030. Omics-based clinical trials integrate advanced omics technologies to collect detailed molecular data from patients participating in clinical studies. Omics encompasses a range of high-throughput techniques used in biology and medicine to analyze biological molecules at the molecular level. These techniques include genomics (the study of genes and DNA), proteomics (the study of proteins), metabolomics (the study of small molecules and metabolites), transcriptomics (the study of RNA and gene expression), and more. A key objective of omics-based clinical trials is to stratify patients into subgroups based on their molecular profiles, enabling more targeted and personalized healthcare interventions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 26.67 Billion
Market Size 2030USD 40.26 Billion
CAGR 2025-20307.25%
Fastest Growing SegmentInterventional Studies
Largest MarketNorth America

However, omics-based clinical trials face challenges such as data standardization, reproducibility issues, and the need for advanced bioinformatics capabilities. The accuracy and reliability of omics data are crucial for successful trials. For example, an article published in April 2024 highlights the growing significance of omics-based biomarkers in managing metabolic dysfunction-associated steatotic liver disease (MASLD), where these biomarkers aid in risk stratification and identifying patients with advanced fibrosis who are at higher risk of adverse outcomes. The increasing adoption of omics-based clinical trials is expected to further propel market growth.

Key Market Drivers:

Advancements in Omics Technologies

Recent developments in high-throughput sequencing have made these techniques faster, more precise, and cost-effective. Technologies like single-cell sequencing enable the examination of genetic material at an individual cell level, revealing cellular heterogeneity. Mass spectrometry tools have become more sensitive and precise, allowing the identification and quantification of proteins and metabolites in complex biological samples. Additionally, advancements in mass spectrometry imaging (MSI) enable the spatial mapping of molecules within tissues. Cryo-electron microscopy (cryo-EM) has revolutionized the structural analysis of proteins, achieving near-atomic resolution. X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy continue to enhance molecular structure resolution. Technologies such as stable isotope labeling and flux analysis offer insights into metabolic pathways, while quantitative proteomics methods, including isobaric labeling and label-free approaches, allow precise protein quantification.

A report from the Mayo Clinic in February 2023 highlights a new approach in genomics research, shifting some omics studies from traditional settings like hospitals to individuals' homes, particularly in rural and underserved areas. This change is expected to improve access to clinical trials, expanding participant pools and enabling more diverse data collection.

Key Market Challenges:

Sample Size and Diversity

One of the challenges of omics-based clinical trials is obtaining an adequate number of patient samples, particularly for rare diseases or genetically specific subpopulations. The availability of diverse patient samples is crucial, as these trials often require large and varied cohorts to generate reliable results. Biological variability among patients within the same disease category can be substantial, making it necessary to include larger sample sizes for statistical validity. Furthermore, ensuring genetic and ethnic diversity in clinical trial populations is essential for the broader applicability of findings. Omics-based trials often involve subgroup analysis based on genetic or molecular characteristics, and recruiting patients that meet these specific criteria can be time-consuming and resource-intensive. Delays in recruitment and data collection can hinder the trial process. Additionally, obtaining informed consent for genetic and molecular profiling, as well as addressing privacy concerns, can also present challenges.

The integration and interpretation of large, complex omics data sets also require advanced bioinformatics tools, which can further complicate the analysis, especially when dealing with large and diverse sample sizes.

Key Market Trends:

Integration of Multi-Omics Data

Different omics technologies provide unique perspectives on the molecular mechanisms underlying diseases. Integrating data from multiple omics disciplines offers a more comprehensive view of disease processes by examining the interplay of genes, proteins, metabolites, and other factors. This integration enhances the identification and validation of biomarkers for disease diagnosis, prognosis, and treatment response. Combining genetic, proteomic, and metabolic profiles leads to more accurate and robust biomarker discovery.

The integration of multi-omics data is pivotal for patient stratification, allowing researchers to classify patients based on molecular profiles and design more targeted clinical trials. This approach also facilitates the development of personalized therapies tailored to individual genetic, proteomic, and metabolic characteristics, leading to more effective treatments. In drug development, multi-omics integration helps to understand how drugs interact with various molecular components, providing insights into potential adverse effects and guiding drug design. For complex diseases like cancer, multi-omics data integration aids in understanding intricate molecular interactions, facilitating the identification of novel therapeutic targets and strategies. This integration aligns with a systems biology approach, offering a holistic understanding of biological systems as interconnected networks of genes, proteins, and metabolites.

Key Market Players:

  • Parexel International Corporation
  • Pharmaceutical Product Development (PPD)
  • Charles River Laboratory
  • ICON plc
  • SGS SA
  • Eli Lilly and Company
  • Pfizer Inc.
  • Covance Inc.
  • Novo Nordisk
  • Rebus Bio

Report Scope:

This report segments the global omics-based clinical trials market into various categories and provides a comprehensive analysis of market trends:

By Phase:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Study Design:

  • Expanded Access Studies
  • Interventional Studies
  • Observational Studies

By Indication:

  • Cardiology
  • CNS Diseases
  • Genetic Diseases
  • Immunology
  • Oncology
  • Respiratory Diseases
  • Skin Diseases

By Region:

  • North America: United States, Canada, Mexico
  • Asia-Pacific: China, India, South Korea, Australia, Japan
  • Europe: Germany, France, United Kingdom, Spain, Italy
  • South America: Brazil, Argentina, Colombia
  • Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape:

This section provides detailed analysis and profiles of the major players in the global omics-based clinical trials market.

Available Customizations:

TechSci Research offers tailored customization options for this market report. These include a detailed analysis of additional market players (up to five) as per specific company needs.

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Omics-Based Clinical Trials Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Phase (Phase I, Phase II, Phase III, and Phase IV.)
    • 5.2.2. By Study Design (Expanded Access Studies, Interventional Studies, and Observational Studies)
    • 5.2.3. By Indication (Cardiology, CNS Diseases, Genetic Diseases, Immunology, Oncology, Respiratory Diseases, and Skin Diseases)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. Asia Pacific Omics-Based Clinical Trials Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Phase
    • 6.2.2. By Study Design
    • 6.2.3. By Indication
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Omics-Based Clinical Trials Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Phase
        • 6.3.1.2.2. By Study Design
        • 6.3.1.2.3. By Indication
    • 6.3.2. India Omics-Based Clinical Trials Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Phase
        • 6.3.2.2.2. By Study Design
        • 6.3.2.2.3. By Indication
    • 6.3.3. Australia Omics-Based Clinical Trials Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Phase
        • 6.3.3.2.2. By Study Design
        • 6.3.3.2.3. By Indication
    • 6.3.4. Japan Omics-Based Clinical Trials Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Phase
        • 6.3.4.2.2. By Study Design
        • 6.3.4.2.3. By Indication
    • 6.3.5. South Korea Omics-Based Clinical Trials Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Phase
        • 6.3.5.2.2. By Study Design
        • 6.3.5.2.3. By Indication

7. Europe Omics-Based Clinical Trials Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Phase
    • 7.2.2. By Study Design
    • 7.2.3. By Indication
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Omics-Based Clinical Trials Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Phase
        • 7.3.1.2.2. By Study Design
        • 7.3.1.2.3. By Indication
    • 7.3.2. Germany Omics-Based Clinical Trials Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Phase
        • 7.3.2.2.2. By Study Design
        • 7.3.2.2.3. By Indication
    • 7.3.3. Spain Omics-Based Clinical Trials Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Phase
        • 7.3.3.2.2. By Study Design
        • 7.3.3.2.3. By Indication
    • 7.3.4. Italy Omics-Based Clinical Trials Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Phase
        • 7.3.4.2.2. By Study Design
        • 7.3.4.2.3. By Indication
    • 7.3.5. United Kingdom Omics-Based Clinical Trials Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Phase
        • 7.3.5.2.2. By Study Design
        • 7.3.5.2.3. By Indication

8. North America Omics-Based Clinical Trials Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Phase
    • 8.2.2. By Study Design
    • 8.2.3. By Indication
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Omics-Based Clinical Trials Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Phase
        • 8.3.1.2.2. By Study Design
        • 8.3.1.2.3. By Indication
    • 8.3.2. Mexico Omics-Based Clinical Trials Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Phase
        • 8.3.2.2.2. By Study Design
        • 8.3.2.2.3. By Indication
    • 8.3.3. Canada Omics-Based Clinical Trials Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Phase
        • 8.3.3.2.2. By Study Design
        • 8.3.3.2.3. By Indication

9. South America Omics-Based Clinical Trials Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Phase
    • 9.2.2. By Study Design
    • 9.2.3. By Indication
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Omics-Based Clinical Trials Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Phase
        • 9.3.1.2.2. By Study Design
        • 9.3.1.2.3. By Indication
    • 9.3.2. Argentina Omics-Based Clinical Trials Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Phase
        • 9.3.2.2.2. By Study Design
        • 9.3.2.2.3. By Indication
    • 9.3.3. Colombia Omics-Based Clinical Trials Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Phase
        • 9.3.3.2.2. By Study Design
        • 9.3.3.2.3. By Indication

10. Middle East and Africa Omics-Based Clinical Trials Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Phase
    • 10.2.2. By Study Design
    • 10.2.3. By Indication
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Omics-Based Clinical Trials Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Phase
        • 10.3.1.2.2. By Study Design
        • 10.3.1.2.3. By Indication
    • 10.3.2. Saudi Arabia Omics-Based Clinical Trials Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Phase
        • 10.3.2.2.2. By Study Design
        • 10.3.2.2.3. By Indication
    • 10.3.3. UAE Omics-Based Clinical Trials Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Phase
        • 10.3.3.2.2. By Study Design
        • 10.3.3.2.3. By Indication

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Omics-Based Clinical Trials Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Parexel International Corporation
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Pharmaceutical Product Development (PPD)
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. Charles River Laboratory
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. ICON plc
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. SGS SA
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. Eli Lilly and Company
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. Pfizer Inc.
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. Covance Inc.
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
  • 16.9. Novo Nordisk
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
  • 16.10.Rebus Bio
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer